A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors

Andexanet Alfa (ANDEXXA)

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

The use of direct oral anticoagulants over traditional warfarin has increased in the United States over the past 10 years because of advantages such as ease of use, predictable pharmacokinetic response, and safety. In 2015, the U.S. Food and Drug Administration approved idarucizumab (Praxbind) for the reversal of the direct thrombin inhibitor dabigatran, but no reversal agent has been available for oral factor Xa (FXa) inhibitors until recently. Andexanet alfa was approved in May 2018, under the brand name ANDEXXA, for the reversal of 2 of FXa inhibitors, apixaban and rivaroxaban, when life-threatening or uncontrolled bleeding occurs. This accelerated approval was based on change in anti-FXa activity from baseline that indicated a reversal of the anticoagulant effect. Any expanded Food and Drug Administration indication will be contingent on results demonstrating improved hemostasis and efficacy for reversing other FXa inhibitors.

Original languageEnglish (US)
Pages (from-to)38-41
Number of pages4
JournalAmerican Journal of Medicine
Volume132
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Anticoagulants
United States Food and Drug Administration
Factor Xa
Antithrombins
Warfarin
Hemostasis
Names
Pharmacokinetics
Hemorrhage
Safety
Factor Xa Inhibitors
PRT064445
idarucizumab
Rivaroxaban
Dabigatran
apixaban

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors : Andexanet Alfa (ANDEXXA). / Rogers, Kelly; Finks, Shannon.

In: American Journal of Medicine, Vol. 132, No. 1, 01.01.2019, p. 38-41.

Research output: Contribution to journalReview article

@article{991a9b8880b34b9e992ccda77eb89158,
title = "A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA)",
abstract = "The use of direct oral anticoagulants over traditional warfarin has increased in the United States over the past 10 years because of advantages such as ease of use, predictable pharmacokinetic response, and safety. In 2015, the U.S. Food and Drug Administration approved idarucizumab (Praxbind) for the reversal of the direct thrombin inhibitor dabigatran, but no reversal agent has been available for oral factor Xa (FXa) inhibitors until recently. Andexanet alfa was approved in May 2018, under the brand name ANDEXXA, for the reversal of 2 of FXa inhibitors, apixaban and rivaroxaban, when life-threatening or uncontrolled bleeding occurs. This accelerated approval was based on change in anti-FXa activity from baseline that indicated a reversal of the anticoagulant effect. Any expanded Food and Drug Administration indication will be contingent on results demonstrating improved hemostasis and efficacy for reversing other FXa inhibitors.",
author = "Kelly Rogers and Shannon Finks",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.amjmed.2018.06.028",
language = "English (US)",
volume = "132",
pages = "38--41",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors

T2 - Andexanet Alfa (ANDEXXA)

AU - Rogers, Kelly

AU - Finks, Shannon

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The use of direct oral anticoagulants over traditional warfarin has increased in the United States over the past 10 years because of advantages such as ease of use, predictable pharmacokinetic response, and safety. In 2015, the U.S. Food and Drug Administration approved idarucizumab (Praxbind) for the reversal of the direct thrombin inhibitor dabigatran, but no reversal agent has been available for oral factor Xa (FXa) inhibitors until recently. Andexanet alfa was approved in May 2018, under the brand name ANDEXXA, for the reversal of 2 of FXa inhibitors, apixaban and rivaroxaban, when life-threatening or uncontrolled bleeding occurs. This accelerated approval was based on change in anti-FXa activity from baseline that indicated a reversal of the anticoagulant effect. Any expanded Food and Drug Administration indication will be contingent on results demonstrating improved hemostasis and efficacy for reversing other FXa inhibitors.

AB - The use of direct oral anticoagulants over traditional warfarin has increased in the United States over the past 10 years because of advantages such as ease of use, predictable pharmacokinetic response, and safety. In 2015, the U.S. Food and Drug Administration approved idarucizumab (Praxbind) for the reversal of the direct thrombin inhibitor dabigatran, but no reversal agent has been available for oral factor Xa (FXa) inhibitors until recently. Andexanet alfa was approved in May 2018, under the brand name ANDEXXA, for the reversal of 2 of FXa inhibitors, apixaban and rivaroxaban, when life-threatening or uncontrolled bleeding occurs. This accelerated approval was based on change in anti-FXa activity from baseline that indicated a reversal of the anticoagulant effect. Any expanded Food and Drug Administration indication will be contingent on results demonstrating improved hemostasis and efficacy for reversing other FXa inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85052877176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052877176&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2018.06.028

DO - 10.1016/j.amjmed.2018.06.028

M3 - Review article

VL - 132

SP - 38

EP - 41

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 1

ER -